查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1726254

全球偏头痛药物市场：市场规模、份额、趋势分析（按药物、药物类别、给药途径、年龄组、获取方式和地区）、细分市场预测（2025-2030 年）

Migraine Drugs Market Size, Share & Trends Analysis Report By Treatment (Acute, Preventive), By Therapeutic Class, By Route Of Administration, By Age Group (Pediatric, Adult, Geriatric), By Availability, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 159 Pages | 商品交期: 2-10个工作天内

价格

偏头痛药物市场的成长与趋势：

根据 Grand View Research, Inc. 的新报告，全球偏头痛药物市场预计到 2030 年将达到 133.4 亿美元，2025 年至 2030 年的复合年增长率为 10.9%。这个市场的主要驱动因素是疾病盛行率上升、新治疗方法的开发、生活方式的改变和荷尔蒙药物等因素。

偏头痛是一种使人衰弱的神经系统疾病，其特征是反覆发作剧烈的搏动性头痛，持续三天或更长时间。偏头痛会随着运动而加剧，并妨碍患者进行正常的日常活动。约三分之一的发作会影响头部、脸部和颈部的两侧。

在过去五年中，全球偏头痛药物市场相对停滞，主要由非专利曲坦类药物和其他仿单标示外用药主导。目前大多数处方药，无论是急性治疗或预防性治疗，疗效都较低且副作用较大。

安进/诺华的 CGRP mAb Aimovig 和梯瓦製药的 Ajovy 的推出是改变偏头痛预防治疗模式的倡议。对于可能在 2019 年进入市场的药品製造商（如礼来公司、Alder BioPharma 和 Biohaven Pharma）而言，定价可能是一个关键的区别因素，因为基于 CGRP 的疗法都具有相似的功效和安全性。

偏头痛药物市场：概述

  • 根据治疗药物，预防部分在 2024 年占据市场最大收入份额，为 62.03%。急性部分在 2024 年占据第二大市场收益占有率。
  • 按治疗层级，CGRP 单株抗体领域在 2024 年占据市场最大收入份额，为 56.68%。 CAGR 预计小分子拮抗剂诊断领域在预测期内将以最快的复合年增长率成长。
  • 根据给药途径，注射剂在 2024 年占据市场主导地位，销售份额最大，为 69.48%。预计口服药物部分在预测期内将呈现显着的复合年增长率。
  • 根据年龄组，成人群体将在 2024 年占据市场最大收益占有率，达到 52.92%，预计在预测期内将以显着的复合年增长率增长。预计在预测期内，老年人群的复合年增长率将显着增长。
  • 根据收购模式，处方药部门将在 2024 年占据市场最大收益占有率，达到 62.38%，预计在预测期内将以显着的复合年增长率成长。

目录

第一章 分析方法与范围

第二章执行摘要

3. 偏头痛药物市场：驱动因素、趋势和范围

  • 市场联动展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制分析
  • 偏头痛药物市场：分析工具
    • 产业分析：波特五力分析
    • PESTEL分析
  • 定价分析
  • 管道分析：按阶段

第四章偏头痛治疗市场：按治疗方式的估计和趋势分析

  • 全球偏头痛药物市场：按疗法分類的仪表板
  • 全球偏头痛药物市场：药物趋势分析
  • 全球偏头痛治疗市场（以收益为准、按治疗）
  • 急性
  • 预防

第五章 偏头痛药物市场：依治疗层级的估计与趋势分析

  • 全球偏头痛药物市场：按治疗层级分類的仪表板
  • 全球偏头痛药物市场：依治疗层级的趋势分析
  • 全球偏头痛药物市场以收益为准与治疗层级
  • CGRP单株抗体
  • CGRP小分子拮抗剂
  • 乙酰胆碱阻断剂/神经毒素
  • 曲坦类
  • 距离
  • 麦角生物碱
  • NSAID
  • 其他的

第六章偏头痛药物市场：依给药途径的估计与趋势分析

  • 全球偏头痛药物市场（依给药途径划分）仪表板
  • 全球偏头痛药物市场：按给药途径变化的分析
  • 全球偏头痛药物市场（以收益为准和给药途径）
  • 口服药物
  • 注射药物
  • 其他的

第七章偏头痛治疗市场：依年龄组别估计与趋势分析

  • 全球偏头痛药物市场：按年龄组别分類的仪表板
  • 全球偏头痛治疗市场：依年龄组别变化分析
  • 全球偏头痛药物市场（以收益为准、按年龄层）
  • 孩子们
  • 成人
  • 老年人

第八章偏头痛药物市场：依来源的估计和趋势分析

  • 全球偏头痛药物市场：Access 仪表板
  • 全球偏头痛药物市场：按获取方式变化的分析
  • 全球偏头痛药物市场以收益为准与取得途径
  • 处方药
  • 场外交易（OTC）

第九章 偏头痛药物市场：按类型（按药物、治疗层级和给药途径）的估计和趋势分析

  • 区域仪表板
  • 市场规模、预测趋势分析，2018 年至 2030 年：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麦
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第十章 竞争格局

  • 主要市场参与企业的近期趋势和影响分析
  • 公司/竞争对手分类
  • 供应商格局
    • 主要经销商和通路合作伙伴名单
    • Key customers
    • Key company market share analysis, 2023
    • AbbVie Inc.
    • Amgen Inc.
    • Teva Pharmaceutical Industries Ltd.
    • GSK plc
    • Eli Lilly and Company
    • Pfizer Inc.
    • Bausch Health Companies Inc.
    • Gensco Pharma
    • Impel Pharmaceuticals Inc.
    • Currax Pharmaceuticals LLC.
    • Lundbeck
Product Code: GVR-2-68038-559-5

Migraine Drugs Market Growth & Trends:

The global migraine drugs market size is expected to reach USD 13.34 billion by 2030, registering a CAGR of 10.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. The market is largely driven by factors such as a rise in disease prevalence, development of novel therapies, lifestyle changes, and hormonal medications.

Migraine is a debilitating neurological disease characterized by recurrent attacks of severe throbbing head pain that can last for more than three days. Migraine pain may get worse on movement, preventing the patient from carrying out normal, day-to-day activities. In about one-third of attacks, both sides of the head, face, or neck are affected.

Over the past five years, the global migraine drugs market has been relatively stagnant, with the market mainly dominated by usage of generic triptans and other off-label drugs. Majority of the currently prescribed drugs for both acute and preventative treatment are associated with poor efficacy and an unfavorable side-effect profile.

Launch of Amgen/ Novartis' CGRP mAb Aimovig and Teva Pharma's Ajovy is the first step toward revolutionizing the treatment paradigm of migraine prevention. For drug manufacturers likely to enter the market by 2019, such as Eli Lilly, Alder BioPharma, and Biohaven Pharma, pricing will be a key differentiating factor as all CGRP-based therapies have a similar efficacy and safety profile.

Migraine Drugs Market Report Highlights:

  • Based on treatment, the preventive segment led the market with the largest revenue share of 62.03% in 2024. The Acute segment held the second largest market revenue share in 2024.
  • Based on the therapeutic class, the CGRP monoclonal antibodies segment led the market with the largest revenue share of 56.68% in 2024. The CGRP small molecule antagonist diagnostics segment is anticipated to grow at the fastest CAGR over the forecast period.
  • Based on the route of administration, the injectable segment led the market with the largest revenue share of 69.48% in 2024. The oral segment is projected to witness a significant CAGR over the forecast period.
  • Based on age group, the adult segment led the market with the largest revenue share of 52.92% in 2024 and is anticipated to grow at a significant CAGR over the forecast period. The geriatric segment is anticipated to grow at a significant CAGR over the forecast period.
  • Based on availability, the prescription drugs segment led the market with the largest revenue share of 62.38% in 2024 and is anticipated to grow at a significant CAGR over the forecast period.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Therapeutic Class
    • 1.2.3. Route of Administration
    • 1.2.4. Age Group
    • 1.2.5. Availability
    • 1.2.6. Regional scope
    • 1.2.7. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment and Therapeutic Class outlook
    • 2.2.2. Route of Administration outlook
    • 2.2.3. Age Group and Availability outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Migraine Drugs Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of migraines
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Migraine Drugs Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
  • 3.4. Pricing Analysis
  • 3.5. Pipeline Analysis, by Phase

Chapter 4. Migraine Drugs Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Migraine Drugs Market: Treatment Dashboard
  • 4.2. Global Migraine Drugs Market: Treatment Movement Analysis
  • 4.3. Global Migraine Drugs Market by Treatment, Revenue
  • 4.4. Acute
    • 4.4.1. Acute market estimates and forecasts, 2018 to 2030 (USD Million)
  • 4.5. Preventive
    • 4.5.1. Preventive market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Migraine Drugs Market: Therapeutic Class Estimates & Trend Analysis

  • 5.1. Global Migraine Drugs Market: Therapeutic Class Dashboard
  • 5.2. Global Migraine Drugs Market: Therapeutic Class Movement Analysis
  • 5.3. Global Migraine Drugs Market by Therapeutic Class, Revenue
  • 5.4. CGRP monoclonal antibodies
    • 5.4.1. CGRP monoclonal antibodies market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.5. CGRP small molecule antagonists
    • 5.5.1. CGRP small molecule antagonists market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.6. Acetylcholine inhibitors/ neurotoxins
    • 5.6.1. Acetylcholine inhibitors/ neurotoxins market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.7. Triptans
    • 5.7.1. Triptans market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.8. Ditans
    • 5.8.1. Ditans market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.9. Ergot alkaloids
    • 5.9.1. Ergot alkaloids market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.10. NSAIDs
    • 5.10.1. NSAIDs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 5.11. Others
    • 5.11.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Migraine Drugs Market: Route of Administration Estimates & Trend Analysis

  • 6.1. Global Migraine Drugs Market: Route of Administration Dashboard
  • 6.2. Global Migraine Drugs Market: Route of Administration Movement Analysis
  • 6.3. Global Migraine Drugs Market by Route of Administration, Revenue
  • 6.4. Oral
    • 6.4.1. Oral market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.5. Injectable
    • 6.5.1. Injectable market estimates and forecasts, 2018 to 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Migraine Drugs Market: Age Group Estimates & Trend Analysis

  • 7.1. Global Migraine Drugs Market: Age Group Dashboard
  • 7.2. Global Migraine Drugs Market: Age Group Movement Analysis
  • 7.3. Global Migraine Drugs Market by Age Group, Revenue
  • 7.4. Pediatric
    • 7.4.1. Pediatric market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.5. Adult
    • 7.5.1. Adult market estimates and forecasts, 2018 to 2030 (USD Million)
  • 7.6. Geriatric
    • 7.6.1. Geriatric market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 8. Migraine Drugs Market: Availability Estimates & Trend Analysis

  • 8.1. Global Migraine Drugs Market: Availability Dashboard
  • 8.2. Global Migraine Drugs Market: Availability Movement Analysis
  • 8.3. Global Migraine Drugs Market by Availability, Revenue
  • 8.4. Prescription Drugs
    • 8.4.1. Prescription Drugs market estimates and forecasts, 2018 to 2030 (USD Million)
  • 8.5. Over-the-Counter (OTC) Drugs
    • 8.5.1. Over-the-Counter (OTC) Drugs market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 9. Migraine Drugs Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. Regulatory framework/ reimbursement structure
      • 9.3.1.3. Competitive scenario
      • 9.3.1.4. U.S. market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Regulatory framework/ reimbursement structure
      • 9.3.2.3. Competitive scenario
      • 9.3.2.4. Canada market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Regulatory framework/ reimbursement structure
      • 9.3.3.3. Competitive scenario
      • 9.3.3.4. Mexico market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. Regulatory framework/ reimbursement structure
      • 9.4.1.3. Competitive scenario
      • 9.4.1.4. UK market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Regulatory framework/ reimbursement structure
      • 9.4.2.3. Competitive scenario
      • 9.4.2.4. Germany market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. Regulatory framework/ reimbursement structure
      • 9.4.3.3. Competitive scenario
      • 9.4.3.4. France market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Regulatory framework/ reimbursement structure
      • 9.4.4.3. Competitive scenario
      • 9.4.4.4. Italy market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Regulatory framework/ reimbursement structure
      • 9.4.5.3. Competitive scenario
      • 9.4.5.4. Spain market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.6. Norway
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Regulatory framework/ reimbursement structure
      • 9.4.6.3. Competitive scenario
      • 9.4.6.4. Norway market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.7. Sweden
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Regulatory framework/ reimbursement structure
      • 9.4.7.3. Competitive scenario
      • 9.4.7.4. Sweden market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.4.8. Denmark
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Regulatory framework/ reimbursement structure
      • 9.4.8.3. Competitive scenario
      • 9.4.8.4. Denmark market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Regulatory framework/ reimbursement structure
      • 9.5.1.3. Competitive scenario
      • 9.5.1.4. Japan market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. Regulatory framework/ reimbursement structure
      • 9.5.2.3. Competitive scenario
      • 9.5.2.4. China market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. Regulatory framework/ reimbursement structure
      • 9.5.3.3. Competitive scenario
      • 9.5.3.4. India market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Regulatory framework/ reimbursement structure
      • 9.5.4.3. Competitive scenario
      • 9.5.4.4. Australia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. Regulatory framework/ reimbursement structure
      • 9.5.5.3. Competitive scenario
      • 9.5.5.4. South Korea market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Regulatory framework/ reimbursement structure
      • 9.5.6.3. Competitive scenario
      • 9.5.6.4. Thailand market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Regulatory framework/ reimbursement structure
      • 9.6.1.3. Competitive scenario
      • 9.6.1.4. Brazil market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Regulatory framework/ reimbursement structure
      • 9.6.2.3. Competitive scenario
      • 9.6.2.4. Argentina market estimates and forecasts, 2018 to 2030 (USD Million)
  • 9.7. Middle East & Africa
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. Regulatory framework/ reimbursement structure
      • 9.7.1.3. Competitive scenario
      • 9.7.1.4. South Africa market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Regulatory framework/ reimbursement structure
      • 9.7.2.3. Competitive scenario
      • 9.7.2.4. Saudi Arabia market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. Regulatory framework/ reimbursement structure
      • 9.7.3.3. Competitive scenario
      • 9.7.3.4. UAE market estimates and forecasts, 2018 to 2030 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Regulatory framework/ reimbursement structure
      • 9.7.4.3. Competitive scenario
      • 9.7.4.4. Kuwait market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 10.2. Company/Competition Categorization
  • 10.3. Vendor Landscape
    • 10.3.1. List of key distributors and channel partners
    • 10.3.2. Key customers
    • 10.3.3. Key company market share analysis, 2023
    • 10.3.4. AbbVie Inc.
      • 10.3.4.1. Company overview
      • 10.3.4.2. Financial performance
      • 10.3.4.3. Product benchmarking
      • 10.3.4.4. Strategic initiatives
    • 10.3.5. Amgen Inc.
      • 10.3.5.1. Company overview
      • 10.3.5.2. Financial performance
      • 10.3.5.3. Product benchmarking
      • 10.3.5.4. Strategic initiatives
    • 10.3.6. Teva Pharmaceutical Industries Ltd.
      • 10.3.6.1. Company overview
      • 10.3.6.2. Financial performance
      • 10.3.6.3. Product benchmarking
      • 10.3.6.4. Strategic initiatives
    • 10.3.7. GSK plc
      • 10.3.7.1. Company overview
      • 10.3.7.2. Financial performance
      • 10.3.7.3. Product benchmarking
      • 10.3.7.4. Strategic initiatives
    • 10.3.8. Eli Lilly and Company
      • 10.3.8.1. Company overview
      • 10.3.8.2. Financial performance
      • 10.3.8.3. Product benchmarking
      • 10.3.8.4. Strategic initiatives
    • 10.3.9. Pfizer Inc.
      • 10.3.9.1. Company overview
      • 10.3.9.2. Financial performance
      • 10.3.9.3. Product benchmarking
      • 10.3.9.4. Strategic initiatives
    • 10.3.10. Bausch Health Companies Inc.
      • 10.3.10.1. Company overview
      • 10.3.10.2. Financial performance
      • 10.3.10.3. Product benchmarking
      • 10.3.10.4. Strategic initiatives
    • 10.3.11. Gensco Pharma
      • 10.3.11.1. Company overview
      • 10.3.11.2. Financial performance
      • 10.3.11.3. Product benchmarking
      • 10.3.11.4. Strategic initiatives
    • 10.3.12. Impel Pharmaceuticals Inc.
      • 10.3.12.1. Company overview
      • 10.3.12.2. Financial performance
      • 10.3.12.3. Product benchmarking
      • 10.3.12.4. Strategic initiatives
    • 10.3.13. Currax Pharmaceuticals LLC.
      • 10.3.13.1. Company overview
      • 10.3.13.2. Financial performance
      • 10.3.13.3. Product benchmarking
      • 10.3.13.4. Strategic initiatives
    • 10.3.14. Lundbeck
      • 10.3.14.1. Company overview
      • 10.3.14.2. Financial performance
      • 10.3.14.3. Product benchmarking
      • 10.3.14.4. Strategic initiatives

List of Tables

  • Table 1. List of abbreviation
  • Table 2. North America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 3. North America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 4. North America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 5. North America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 6. North America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 7. North America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 8. U.S. Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 9. U.S. Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 10. U.S. Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 11. U.S. Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 12. U.S. Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 13. Canada Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 14. Canada Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 15. Canada Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 16. Canada Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 17. Canada Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 18. Europe Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 19. Europe Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 20. Europe Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 21. Europe Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 22. Europe Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 23. Europe Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 24. Germany Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 25. Germany Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 26. Germany Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 27. Germany Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 28. Germany Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 29. UK Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 30. UK Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 31. UK Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 32. UK Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 33. UK Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 34. France Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 35. France Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 36. France Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 37. France Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 38. France Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 39. Italy Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 40. Italy Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 41. Italy Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 42. Italy Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 43. Italy Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 44. Spain Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 45. Spain Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 46. Spain Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 47. Spain Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 48. Spain Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 49. Denmark Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 50. Denmark Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 51. Denmark Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 52. Denmark Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 53. Denmark Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 54. Sweden Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 55. Sweden Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 56. Sweden Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 57. Sweden Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 58. Sweden Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 59. Norway Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 60. Norway Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 61. Norway Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 62. Norway Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 63. Norway Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 67. Aisa Pacific Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 68. Asia Pacific Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 69. Aisa Pacific Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 70. China Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 71. China Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 72. China Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 73. China Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 74. China Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 75. Japan Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 76. Japan Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 77. Japan Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 78. Japan Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 79. Japan Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 80. India Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 81. India Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 82. India Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 83. India Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 84. India Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 85. South Korea Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 86. South Korea Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 87. South Korea Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 88. South Korea Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 89. South Korea Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 90. Australia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 91. Australia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 92. Australia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 93. Australia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 94. Australia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 95. Thailand Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 96. Thailand Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 97. Thailand Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 98. Thailand Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 99. Thailand Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 100. Latin America Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 101. Latin America Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 102. Latin America Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 103. Latin America Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 104. Latin America Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 105. Latin America Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 106. Brazil Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 107. Brazil Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 108. Brazil Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 109. Brazil Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 110. Brazil Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 111. Mexico Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 112. Mexico Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 113. Mexico Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 114. Mexico Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 115. Mexico Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 116. Argentina Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 117. Argentina Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 118. Argentina Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 119. Argentina Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 120. Argentina Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 121. MEA Migraine Drugs market, by region, (USD Million) 2018 - 2030 (USD Million)
  • Table 122. MEA Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 123. MEA Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 124. MEA Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 125. MEA Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 126. MEA Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 127. South Africa Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 128. South Africa Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 129. South Africa Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 130. South Africa Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 131. South Africa Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 132. Saudi Arabia Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 133. Saudi Arabia Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 134. Saudi Arabia Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 135. Saudi Arabia Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 136. Saudi Arabia Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 137. UAE Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 138. UAE Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 139. UAE Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 140. UAE Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 141. UAE Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)
  • Table 142. Kuwait Migraine Drugs market, by Treatment, (USD Million) 2018 - 2030 (USD Million)
  • Table 143. Kuwait Migraine Drugs market, by Therapeutic Class, (USD Million) 2018 - 2030 (USD Million)
  • Table 144. Kuwait Migraine Drugs market, by Route of Administration, (USD Million) 2018 - 2030 (USD Million)
  • Table 145. Kuwait Migraine Drugs market, by Age Group, (USD Million) 2018 - 2030 (USD Million)
  • Table 146. Kuwait Migraine Drugs market, by Availability, (USD Million) 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Primary interviews in North America
  • Fig. 5 Primary interviews in Europe
  • Fig. 6 Primary interviews in APAC
  • Fig. 7 Primary interviews in Latin America
  • Fig. 8 Primary interviews in MEA
  • Fig. 9 Market research approaches
  • Fig. 10 Value-chain-based sizing & forecasting
  • Fig. 11 QFD modeling for market share assessment
  • Fig. 12 Market formulation & validation
  • Fig. 13 Migraine Drugs market: market outlook
  • Fig. 14 Migraine Drugs competitive insights
  • Fig. 15 Parent market outlook
  • Fig. 16 Related/ancillary market outlook
  • Fig. 17 Migraine Drugs market driver impact
  • Fig. 18 Migraine Drugs market restraint impact
  • Fig. 19 Migraine Drugs market: Treatment movement analysis
  • Fig. 20 Migraine Drugs market: Treatment outlook and key takeaways
  • Fig. 21 Acute market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Preventive estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Migraine Drugs market: Therapeutic Class movement analysis
  • Fig. 24 Migraine Drugs market: Therapeutic Class outlook and key takeaways
  • Fig. 25 CGRP monoclonal antibodies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 CGRP small molecule antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Acetylcholine inhibitors/ neurotoxins market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Triptans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Ditans market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 31 NSAIDs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 32 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Migraine Drugs market: Route of Administration movement analysis
  • Fig. 34 Migraine Drugs market: Route of Administration outlook and key takeaways
  • Fig. 35 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Injectable market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 38 Migraine Drugs market: Age Group movement analysis
  • Fig. 39 Migraine Drugs market: Age Group outlook and key takeaways
  • Fig. 40 Pediatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Adult market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Geriatric market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Migraine Drugs market: Availability movement analysis
  • Fig. 44 Migraine Drugs market: Availability outlook and key takeaways
  • Fig. 45 Prescription Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 46 Over-the-Counter (OTC) Drugs market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 47 Global Migraine Drugs market: Regional movement analysis
  • Fig. 48 Global Migraine Drugs market: Regional outlook and key takeaways
  • Fig. 49 Global Migraine Drugs market share and leading players
  • Fig. 50 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 US key country dynamics
  • Fig. 52 US market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Canada key country dynamics
  • Fig. 54 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 UK key country dynamics
  • Fig. 57 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Germany key country dynamics
  • Fig. 59 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 France key country dynamics
  • Fig. 61 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Italy key country dynamics
  • Fig. 63 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Spain key country dynamics
  • Fig. 65 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Denmark key country dynamics
  • Fig. 67 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Sweden key country dynamics
  • Fig. 69 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Norway key country dynamics
  • Fig. 71 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 72 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 China key country dynamics
  • Fig. 74 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 75 Japan key country dynamics
  • Fig. 76 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 77 India key country dynamics
  • Fig. 78 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Thailand key country dynamics
  • Fig. 80 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 81 South Korea key country dynamics
  • Fig. 82 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Australia key country dynamics
  • Fig. 84 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 85 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 86 Brazil key country dynamics
  • Fig. 87 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 88 Mexico key country dynamics
  • Fig. 89 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Argentina key country dynamics
  • Fig. 91 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 92 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 South Africa key country dynamics
  • Fig. 94 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 95 Saudi Arabia key country dynamics
  • Fig. 96 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 97 UAE key country dynamics
  • Fig. 98 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 99 Kuwait key country dynamics
  • Fig. 100 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Market share of key market players - Migraine Drugs market